PubRank

PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors.

PubWeight™: 0.81‹?›

🔗 View Article (PMID 24486569)

Published in Biochem Pharmacol on January 31, 2014

Authors

Marta Martínez-Díez1, María José Guillén-Navarro1, Benet Pera2, Benjamin Pierre Bouchet3, Juan Fernando Martínez-Leal1, Isabel Barasoain2, Carmen Cuevas1, Jose M Andreu2, Luis Francisco García-Fernández1, J Fernando Díaz2, Pablo Avilés1, Carlos M Galmarini4

Author Affiliations

1: PharmaMar S.A., Avda de los Reyes 1, Polígono Industrial La Mina, Colmenar Viejo, 28770 Madrid, Spain.
2: Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu 9, 28040 Madrid, Spain.
3: Centre Léon Bérard, Lyon F-69373, France.
4: PharmaMar S.A., Avda de los Reyes 1, Polígono Industrial La Mina, Colmenar Viejo, 28770 Madrid, Spain. Electronic address: cgalmarini@pharmamar.com.

Articles citing this ↘

A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. Proc Natl Acad Sci U S A (2014) 1.00

Compounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cells. Oncotarget (2016) 0.75

The Bengamides: A Mini-Review of Natural Sources, Analogues, Biological Properties, Biosynthetic Origins, and Future Prospects. J Nat Prod (2017) 0.75

KUD773, a phenylthiazole derivative, displays anticancer activity in human hormone-refractory prostate cancers through inhibition of tubulin polymerization and anti-Aurora A activity. J Biomed Sci (2015) 0.75